BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• BRCA1 and BRCA2 gene mutations are key indicators of hereditary breast and ovarian cancer risk.
• Identifying these mutations is crucial for patient eligibility for targeted therapies like PARP inhibitors.
• Existing testing methods require optimization for high-throughput analysis to meet growing demand.

Purpose of the Study:

• To develop and validate a cost-effective, time-efficient workflow for BRCA1-BRCA2 mutation detection using Ion Torrent PGM technology.
• To establish a standardized, user-friendly process suitable for certified laboratory implementation.
• To enhance the identification of patients eligible for personalized cancer treatments.

Main Methods:

• Utilized Ion Torrent PGM next-generation sequencing technology.
• Developed a comprehensive workflow from library preparation to final reporting.
• Analyzed a retrospective cohort (40 patients) and a prospective validation set (72 patients) including familial and sporadic cancer cases.

Main Results:

• Successfully established and validated a standardized, cost-effective, and low time-consuming BRCA1-BRCA2 mutation detection workflow.
• The workflow is suitable for implementation in certified diagnostic laboratories.
• Demonstrated the utility of next-generation sequencing for patient genetic counseling and personalized treatment selection.

Conclusions:

• The developed Ion Torrent PGM workflow provides a reliable and efficient method for BRCA1-BRCA2 mutation detection.
• This approach supports genetic counseling and improves the selection of patients for PARP inhibitor therapies.
• Implementing high-throughput sequencing technologies is essential for advancing personalized cancer care.